BIOMAT Database Logo BIOMAT Database Logo

24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease. 2016

Lucia Ricciardi, and Francesco Bove, and Kristy J Espay, and Francesco Lena, and Nicola Modugno, and Yu-Yan Poon, and Robert Krikorian, and Alberto J Espay, and Alfonso Fasano
Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, University College London, London, UK.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009127 Muscle Rigidity Continuous involuntary sustained muscle contraction which is often a manifestation of BASAL GANGLIA DISEASES. When an affected muscle is passively stretched, the degree of resistance remains constant regardless of the rate at which the muscle is stretched. This feature helps to distinguish rigidity from MUSCLE SPASTICITY. (From Adams et al., Principles of Neurology, 6th ed, p73) Cogwheel Rigidity,Extrapyramidal Rigidity,Gegenhalten,Nuchal Rigidity,Rigidity, Muscular,Catatonic Rigidity,Extensor Rigidity,Cogwheel Rigidities,Gegenhaltens,Muscular Rigidity,Rigidities, Cogwheel,Rigidity, Catatonic,Rigidity, Cogwheel,Rigidity, Extensor,Rigidity, Extrapyramidal,Rigidity, Muscle,Rigidity, Nuchal
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D002230 Carbidopa An inhibitor of DOPA DECARBOXYLASE that prevents conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no anti-parkinson activity by itself. Methyldopahydrazine,Carbidopa, (R)-Isomer,Carbidopa, (S)-Isomer,Lodosin,Lodosyn,MK-485,MK-486,MK 485,MK 486,MK485,MK486
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

Lucia Ricciardi, and Francesco Bove, and Kristy J Espay, and Francesco Lena, and Nicola Modugno, and Yu-Yan Poon, and Robert Krikorian, and Alberto J Espay, and Alfonso Fasano
24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson's disease.
January 2018, NPJ Parkinson's disease,
Lucia Ricciardi, and Francesco Bove, and Kristy J Espay, and Francesco Lena, and Nicola Modugno, and Yu-Yan Poon, and Robert Krikorian, and Alberto J Espay, and Alfonso Fasano
Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease.
August 2012, European journal of neurology,
Lucia Ricciardi, and Francesco Bove, and Kristy J Espay, and Francesco Lena, and Nicola Modugno, and Yu-Yan Poon, and Robert Krikorian, and Alberto J Espay, and Alfonso Fasano
Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.
April 2013, The AAPS journal,
Lucia Ricciardi, and Francesco Bove, and Kristy J Espay, and Francesco Lena, and Nicola Modugno, and Yu-Yan Poon, and Robert Krikorian, and Alberto J Espay, and Alfonso Fasano
Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.
May 2011, Current medical research and opinion,
Lucia Ricciardi, and Francesco Bove, and Kristy J Espay, and Francesco Lena, and Nicola Modugno, and Yu-Yan Poon, and Robert Krikorian, and Alberto J Espay, and Alfonso Fasano
Continuous infusion of levodopa-carbidopa intestinal gel in Parkinson's disease.
July 2014, Journal of comparative effectiveness research,
Lucia Ricciardi, and Francesco Bove, and Kristy J Espay, and Francesco Lena, and Nicola Modugno, and Yu-Yan Poon, and Robert Krikorian, and Alberto J Espay, and Alfonso Fasano
Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience.
February 2014, European journal of neurology,
Lucia Ricciardi, and Francesco Bove, and Kristy J Espay, and Francesco Lena, and Nicola Modugno, and Yu-Yan Poon, and Robert Krikorian, and Alberto J Espay, and Alfonso Fasano
Long-term safety and efficacy of 24-hour levodopa-carbidopa intestinal gel in Parkinson's disease.
November 2019, Movement disorders : official journal of the Movement Disorder Society,
Lucia Ricciardi, and Francesco Bove, and Kristy J Espay, and Francesco Lena, and Nicola Modugno, and Yu-Yan Poon, and Robert Krikorian, and Alberto J Espay, and Alfonso Fasano
Long-term 24-h levodopa/carbidopa gel infusion in Parkinson's disease.
September 2012, Parkinsonism & related disorders,
Lucia Ricciardi, and Francesco Bove, and Kristy J Espay, and Francesco Lena, and Nicola Modugno, and Yu-Yan Poon, and Robert Krikorian, and Alberto J Espay, and Alfonso Fasano
[Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
December 2015, Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology,
Lucia Ricciardi, and Francesco Bove, and Kristy J Espay, and Francesco Lena, and Nicola Modugno, and Yu-Yan Poon, and Robert Krikorian, and Alberto J Espay, and Alfonso Fasano
Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease.
March 2014, Journal of neurology,
Copied contents to your clipboard!